Stockscreener 앱 받기
607.93
1.11%
-6.80
시간 외 거래:
605.80
-2.13
-0.35%
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Regeneron Pharmaceuticals Stock (US75811P1003): Analyst coverage and fundamentals in focus - AD HOC NEWS
Regeneron Pharma Stock (US75886F1075): Valuation In Focus After Recent Pullback - AD HOC NEWS
Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations - simplywall.st
(REGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN) Shareholder/Analyst CallSlideshow (NASDAQ:REGN) 2026-06-12 - Seeking Alpha
REGN: All board proposals passed as strong growth and pipeline advances were highlighted - TradingView
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Parabilis Medicines closes $770.5m IPO, Regeneron investment By Investing.com - Investing.com Canada
Regeneron backs Parabilis (PBLS) with IPO private placement and new charter - Stock Titan
Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance Singapore
Regeneron Keeps Biotech Execution In Focus Amid Market Volatility - Kalkine Media
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now? - Insider Monkey
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy - BioPharma Dive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Regeneron-backed Parabilis rises on market debut (REGN:NASDAQ) - Seeking Alpha
Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak - Insider Monkey
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO - marketscreener.com
Parabilis Medicines (PBLS) launches IPO with $75M Regeneron private placement - Stock Titan
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight - Barchart.com
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
5 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Daiwa Securities Group Inc. Sells 2,058 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading - AD HOC NEWS
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Alvotech targets J&J’s Simponi and Regeneron’s Eylea (ALVO) - Seeking Alpha
Cambridge biotech plans $450M IPO with Regeneron backing - The Business Journals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
With Strong Cash Flow, Regeneron Pharmaceuticals Stock Poised to Rise? - Trefis
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
2026-06-04 | Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
CytomX expands collaboration with Regeneron - The Pharma Letter
1.57%
0.47%
자본화:
|
볼륨(24시간):